Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Progen Pharmaceuticals Identifier:
First received: February 16, 2006
Last updated: June 21, 2016
Last verified: June 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: No date given
  Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)